Abstract Aims/hypothesis: New insulin analogues have been created by amino-acid exchange to provide an improved pharmacokinetic profile. However, safety issues have been raised regarding their use, as amino-acid exchange of insulin may induce altered metabolic and mitogenic effects. For example, the insulin analogue Asp(B10) causes breast cancer in rodents. 
Introduction
In the past few years insulin analogues have been introduced for the treatment of diabetes [1] . There are now two rapid-acting insulin analogues and two long-acting insulin analogues on the market [2] [3] [4] [5] . When modifying the pharmacokinetic profile by introducing mutations into the insulin gene, it is crucial that these insulin analogues still behave like regular insulin with respect to insulin receptor binding and activation. Moreover, they should trigger similar intracellular signalling pathways. Keeping in mind that the initiation of insulin therapy is most often followed by life-long treatment, the issue of mitogenic effects is very important when testing new insulin analogues. Previous studies have shown that the insulin analogue Asp(B10) behaves differently from regular insulin with respect to dissociation from the insulin receptor, phosphorylation and dephosphorylation of substrates, and mitogenic activity in different cell lines [6] [7] [8] [9] .
Although the exact mechanisms for the enhanced mitogenic potential of Asp(B10 ) have not yet been elucidated, it seems to be related to a delayed insulin receptor dissociation and dephosphorylation rate and due to phos-phorylation of different substrates [10] . It has, moreover, been shown that Asp(B10) displays increased binding to the IGF-I receptor, which can also contribute to mitogenic activity [11, 12] .
By introducing amino-acid exchange, the physicochemical properties of regular human insulin were changed, creating the new rapid-acting insulin analogue, insulin glulisine (HMR1964, Lys[B3],Glu[B29]). The mutations of HMR1423 (Gly[A21],His[B31],His[B32]) introduced two additional histidines serving as additional zinc-binding sites. This makes HMR1423 a potential tool for an insulin analogue with a prolonged, or even variable, duration of insulin action (depending on the proportion of HMR1423 in a mixed preparation with non-mutated insulin). The aim of this study was to investigate the insulin receptor binding and autophosphorylation characteristics of the abovementioned insulin analogues in rat-1 fibroblasts, and their mitogenicity in the non-malignant human breast cell line MCF10 [13] compared with regular human insulin and Asp(B10).
Materials and methods

Materials
Cell culture reagents and fetal calf serum were purchased from Gibco (Karlsruhe, Germany). Aprotinin, phenylmethylsulphonyl fluoride, Na 3 VO 4 and Triton X-100 were from Sigma (Munich, Germany). Nitrocellulose was from Sartorius (Göttingen, Germany). Visualisation of immunocomplexes after western blotting was performed with the non-radioactive enhanced chemiluminescence system from Amersham Biosciences Europe (Freiburg, Germany). [ 3 H]Thymidine was purchased from Amersham Biosciences Europe. The monoclonal anti-phosphotyrosine (PTYR) antibody (PY20) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All insulins used in this study were supplied by Aventis Pharmaceuticals (Bad Soden, Germany).
Cell culture and western blot analysis
Rat-1 fibroblasts stably overexpressing human insulin receptor isoform B (HIR-B) were grown in DMEM/Ham's F12 medium mix supplemented with 10% FCS. Cells were grown to confluence, and subsequently starved for 18 h, in medium with 0.5% FCS, and then incubated with regular human insulin, or the analogues, as indicated in the figures.
Receptor autophosphorylation was measured as previously described [10] . For dephosphorylation kinetics, HIR-B-overexpressing cells were incubated with regular human insulin, or analogues, for 3 min. Dephosphorylation of the insulin receptor was initiated by washing off the insulin. Cells were lysed, on ice, with 50 mmol/l HEPES buffer containing 150 mmol/l NaCl, 1.5 mmol/l MgCl 2 , 1 mmol/l EGTA, 10% glycerol, 1% Triton X-100, 1 mmol/ l phenylmethylsulphonyl fluoride, 10 mg/l aprotinin, 0.4 mmol/l orthovanadate, 10 mmol/l Na 4 P 2 O 7 , and 100 mmol/l NaF after various time intervals (0-60 min). After centrifugation, supernatants were boiled in Laemmli buffer, and proteins were separated by 7.5% SDS-PAGE. Proteins were transferred to nitrocellulose membranes and blotted with anti-PTYR antibody or anti-insulin-receptor antibody (CT 104), overnight at 4°C. The membranes were washed four times before incubating with horseradish peroxidase-conjugated anti-mouse IgG, or anti-rabbit IgG, for 1 h at room temperature. Visualisation of immunocomplexes was performed by enhanced chemiluminescence. 10 Bq/mg) and incubated at 21°C for the times indicated. Radioactivity was measured in a gamma counter. Non-specific binding was determined in the presence of excess unlabelled insulin. 4 Bq/ml) was added for 4 h. The dishes were then rinsed twice with icecold PBS, and once with 10% trichloroacetic acid. After 20 min, dishes were washed once with ice-cold 10% trichloroacetic acid, cells were lysed with 500 μl 0.2 mol/ l NaOH/1% SDS, and neutralised with 0.5 ml 0.2 mol/ l HCl. Radioactivity was determined by liquid scintillation counting.
Statistics
Statistical analyses were carried out by Student's t-test. Data in figures are expressed as means±SEM. p values less than 0.05 were considered significant.
Results
Insulin receptor association kinetics
It has been shown that insulin analogues can exhibit altered receptor-binding characteristics. We examined association kinetics of HMR1964 (insulin glulisine) and HMR1423 in rat-1 fibroblasts overexpressing approximately 1,250,000 insulin receptors per cell (HIR-B) to estimate specific binding to the human insulin receptor. For HMR1964, HMR1423 and regular insulin, similar receptor association kinetics were observed (Fig. 1) . In contrast, Asp(B10) showed markedly increased insulin receptor binding affinity (bound insulin 10.96±2.61% of total) compared with regular insulin (5.28±1.78%). Therefore, only Asp(B10) insulin behaved differently with respect to affinity for the insulin receptor.
Insulin competition curves
The inhibition of -10 −10 mol/l, final concentration). In HIR-B cells, 125 I-Asp(B10) binding was inhibited by unlabelled regular insulin with an EC 50 effect at ∼60 nmol/l, for HMR1964 the EC 50 effect was at ∼70 nmol/l and at ∼80 nmol/l for HMR1423, whereas Asp (B10) was approximately 10-fold more potent in competing for insulin receptor binding compared with regular human insulin (EC 50 ∼6 nmo/l) (Fig. 2) .
Insulin receptor dissociation kinetics
The dissociation rate was measured by incubating HIR-B cells with labelled insulin or the analogues over a 45-min period. To minimise internalisation, the experiment was carried out at 4°C and the results are expressed as a percentage of the initial binding. Asp(B10) dissociated significantly more slowly from the receptor, whereas the analogues HMR1964 and HMR1423 dissociated more rapidly and to the same extent as regular insulin (Fig. 3) .
Insulin receptor autophosphorylation kinetics
To determine the effect on insulin receptor autophosphorylation, we stimulated rat-1 fibroblasts overexpressing HIR-B with either regular insulin or the insulin analogues for 3-120 min. Insulin receptor activation by autophosphorylation was detected by western blot analysis of whole-cell lysates, using an anti-PTYR antibody (Fig. 4a) . Protein levels of insulin receptor were assessed by western blot analysis with an anti-receptor β-subunit antibody (Fig. 4b) .
In HIR-B cells, regular insulin and the new analogues showed no significant differences in receptor autophosphorylation, while different kinetics were observed with Asp(B10). Each of the new analogues induced rapid autophosphorylation of the insulin receptor, reaching a maximum after 10 min of stimulation with 10 −9 mmol/l insulin. Despite rapid autophosphorylation, Asp(B10) insulin induced a prolonged phosphorylation state of the insulin receptor β-subunit, which could still be observed at 120 min, a time-point where autophosphorylation by the other analogues was already reduced (quantification of six different experiments is depicted in Fig. 4c ).
Dephosphorylation kinetics of the insulin receptor
Dephosphorylation kinetics for regular insulin and the analogues HMR1964, HMR1423 and Asp(B10) were assessed by incubating HIR-B cells with the respective ligand. After a 3-min incubation, insulin was washed off and dephosphorylation was measured between 3 and 60 min. Representative western blots are shown in Fig. 5a ,b. Delayed dephosphorylation of the insulin receptor was observed in rat-1 cells stimulated with Asp(B10), while HMR1964 and HMR1423 behaved like regular human insulin (Fig. 5a) . Quantification of five different experi- [10, 14] . In contrast, the insulin analogue HMR1423 behaved like regular insulin, while HMR1964 was even less effective in stimulation of [ 3 H]thymidine incorporation (Fig. 6 ).
Discussion
Insulin analogues have been created to improve therapy of diabetic patients. When introducing point mutations in the insulin gene, metabolic as well as mitogenic effects must be tested carefully in a preclinical and clinical setting. Since the concentrations of insulin or insulin analogues which might cause mitogenesis through the IGF-I receptor are unlikely to occur in vivo, it is a major concern that an insulin analogue might cause mitogenic effects, not via the IGF-I receptor, but via the insulin receptor. Therefore, we examined insulin receptor association and dissociation kinetics as well as auto-and dephosphorylation of the insulin receptor after stimulation with the new rapid-acting insulin analogues insulin glulisine (HMR1964) and the potentially long-acting analogue HMR1423.
Compared with regular human insulin, we found similar receptor binding characteristics and insulin receptor autophosphorylation and dephosphorylation kinetics for these two new analogues. These findings are in contrast to Asp(B10) insulin, which shows markedly increased affinity for the insulin receptor and prolonged insulin receptor auto-and dephosphorylation rates. This altered behaviour of Asp(B10) on the insulin receptor goes along with increased mitogenic activity shown in rat-1 fibroblasts [10] as well as in MCF10 cells [14] . Moreover Asp(B10) induced tumour formation in mammary glands of rats [14] . While this suggests that the mitogenic effects of Asp(B10) are mediated by the insulin receptor itself, Kurtzhals et al. [15] reported that increased IGF-I binding of insulin analogues may contribute to mitogenicity. However, increased affinity to the IGF-I receptor appears not to be the only mechanism for increased mitogenicity, given that some insulin analogues, like lispro, do not show increased mitogenicity, although their IGF-I receptor binding is somewhat increased. Therefore, under physiological concentrations of insulin, mitogenic properties are much more likely to be determined by the effect of the insulin analogues on the insulin receptor itself. This is in agreement with a report from Hansen et al. [16] showing that the mitogenic effects of different insulin analogues can be predicted by a reduced dissociation rate from the insulin receptor. Indeed, this might be an important mechanism for the increased mitogenic activity of Asp(B10) insulin, since this insulin shows prolonged occupancy on the insulin receptor, which may allow coupling to mitogenic signalling pathways.
Mitogenic activity of the insulin analogues was also tested in the non-malignant human epithelial breast cell line MCF10. This cell line has several advantages over other frequently used malignant cell lines. First, increased mitogenic activity has already been demonstrated with Asp (B10) in this cell model [10] . Secondly, Asp(B10) induced increased mammary tumours in rodents [14] , suggesting that mammary cells represent a relevant tissue to study mitogenic effects. Thirdly, MCF10 cells express both insulin receptor isoforms (A and B) to the same extent, as there is increasing evidence that the HIR-A is of prime importance for mitogenic signalling [17] .
In this non-malignant cell line, Asp(B10) was more potent in stimulating [ 3 H]thymidine incorporation, while HMR1423 and regular insulin showed no differences, and HMR1964 was even less mitogenic than regular insulin. A reasonable mechanism for the decreased mitogenic activity of HMR1964 was recently suggested by Rakatzi et al. [18] , who demonstrated in an in vitro model that HMR1964 shows lower IRS-1 phosphorylation than regular insulin.
In summary, our data show that the new insulin analogues insulin glulisine (HMR1964) and HMR1423 behave like regular human insulin in terms of insulin receptor binding and phosphorylation characteristics. Moreover, HMR1964 was even less mitogenic than regular human insulin in MCF10 cells. Therefore, these new insulin analogues may be safe in terms of mitogenicity. However, as with all new insulin analogues, its side-effects and mitogenic potential must be fully evaluated in vivo.
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